Company Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.
Country | United States |
IPO Date | n/a |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 183 |
CEO | Dr. Laura E. Niklason M.D., Ph.D. |
Contact Details
Address: No Address available No city data available, United States | |
Website | n/a |
Stock Details
Ticker Symbol | HUMAW |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001818382 |
CUSIP Number | 44486Q111 |
ISIN Number | US44486Q1114 |
Employer ID | 85-1763759 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, Chief Executive Officer & Director |
Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer & Treasurer |
Dr. Heather Ledbetter Prichard Ph.D. | Chief Operating Officer |
Sabrina Osborne GPHR, SPHR | Chief People Officer |
Dr. Shamik J. Parikh M.D. | Chief Medical Officer |
Dr. Yang Cao M.D., Ph.D. | Chief Regulatory Officer |
Harold Alterson | Chief Quality Officer |
William John Scheessele | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 04, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 20, 2024 | SC 13D/A | [Amend] Filing |
Nov 20, 2024 | 4 | Filing |
Nov 20, 2024 | 4 | Filing |
Nov 18, 2024 | SC 13D/A | [Amend] Filing |
Nov 14, 2024 | 8-K | Current Report |
Nov 14, 2024 | 424B3 | Filing |
Nov 08, 2024 | 10-Q | Quarterly Report |